peptide-safety-incident
peptide-safety-incident
The prediction
By 2027-03-31, a top-5 US news outlet (NYT, WSJ, CNN, NPR, WaPo) publishes a major feature on peptide injuries, contamination, or deaths sourced from compounded/gray-market products
Adoption at current velocity plus 40 percent contamination rate plus minimal regulation equals statistical certainty of adverse event. Media narrative arc typically runs hype-phase to backlash-phase within 12-18 months. Already have safety-focused coverage seeding (NPR Feb 2026, UNSW April 2026). Counter-narrative ~30%: FDA enforcement of gray-market sellers tightens fast enough to prevent headline-grade incident; industry self-regulation via compounders catches contamination early.
Trajectory
- 19 April 2026 · created70%signal strength 61
Adoption at current velocity plus 40 percent contamination rate plus minimal regulation equals statistical certainty of adverse event. Media narrative arc typically runs hype-phase to backlash-phase within 12-18 months. Already have safety-focused coverage seeding (NPR Feb 2026, UNSW April 2026). Counter-narrative ~30%: FDA enforcement of gray-market sellers tightens fast enough to prevent headline-grade incident; industry self-regulation via compounders catches contamination early.
- 2026-04-19 07:00 UTC · Ra run· flagged70%0· signal 63
No new evidence today but reference-class widened to include NMN/NAC/ConsumerLab creatine/2008 heparin analogues. Base rate likely closer to 0.50 than original 0.70. Internal flag for full re-price next Sunday.
Counter-narrativeIndustry may self-regulate via compounders catching contamination before a headline-grade incident
- 2026-04-22 04:04 UTC · Ra runread brief →65%-0.05· signal 58
WaPo April 15 feature seeds the narrative but covers regulation, not injuries/deaths. Medscape secret-shopper study demonstrates journalistic method exists. 12-58% contamination rate in unregulated products is the fuel. However: Cat 2 removal + reclassification to Cat 1 could paradoxically REDUCE risk by moving production to regulated 503A/B pharmacies. Dual-direction signal warrants modest downward revision. Prior re-price flag from Sunday acknowledged.
Counter-narrativeReclassification to Cat 1 may improve safety by channeling demand from gray-market to regulated compounders, reducing probability of headline incident
- 2026-04-22 10:52 UTC · Ra run· flaggedread brief →62%-0.03· signal 57
Second-pass (10:52 UTC). KEY DIVERGENCE from 15:30 run: FDA explicitly stated no spike in adverse events from compounded peptides. This is a strong negative signal the 15:30 run did not capture. Argues for 0.62 vs 15:30 run's 0.65 hold. Flagging for operator adjudication.
Counter-narrativeReclassification channels demand to regulated 503A/B compounders reducing gray-market share and incident probability; FDA reports no adverse event spike
- 2026-04-22 15:30 UTC · Ra runread brief →65%0· signal 58
Dual-direction signals cancel. ProPublica + Woodcock building investigative narrative infrastructure for safety backlash. But Cat 1 reclassification could reduce gray-market sourcing, paradoxically improving safety. No new actual incidents reported. Media is positioned to amplify whatever occurs — the journalistic template exists.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders, shrinking gray-market and reducing contamination incidents
- 2026-04-23 07:04 UTC · Ra runread brief →65%0· signal 58
No new incidents. FDA no-adverse-event-spike finding confirmed. Unresolved adjudication (0.62 vs 0.65) from April 22 persists — operator input needed.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing contamination and incident probability
- 2026-04-24 07:04 UTC · Ra runread brief →63%-0.02· signal 57
Resolving April 22 adjudication (0.62 vs 0.65). FDA no-adverse-event-spike signal captured in 10:52 run warrants acknowledgment. Cat 1 channeling paradox reduces gray-market risk. Settling at 0.63.
Counter-narrativeAdoption velocity increases absolute adverse events even as contamination rate may fall under Cat 1 channeling; ProPublica and WaPo have investigative templates ready
- 2026-04-25 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. Reclassification literature emphasizes USP 797/795 standards for regulated compounders. Research-use-only peptides still sold online. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination risk
- 2026-04-26 07:04 UTC · Ra runread brief →63%0· signal 57
1000+ adverse events on compounded GLP-1s by mid-2025 and GHRP-2 deaths documented. 8% endotoxin contamination in gray-market. But FDA says no spike from compounded peptides specifically. Dual-direction signals cancel. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination risk
- 2026-04-27 07:04 UTC · Ra runread brief →63%0· signal 57
Weekly review: no new adverse events. FDA confirmed no spike from compounded peptides. Dual-direction equilibrium holds (Cat 1 reduces gray-market risk; adoption velocity increases exposure). ProPublica/WaPo templates positioned but no named victim story. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-04-28 04:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. FDA no-spike finding stands. Research-use-only peptides still sold online. Media templates positioned but no trigger event. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-04-29 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. PMC immunogenicity paper and UVA Q&A are academic substrate not media catalysts. Journalistic templates positioned but no named victim. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-04-30 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. Immunogenicity review (PMC) reinforces academic safety substrate. Gray-market contamination rates unchanged. Journalistic templates positioned but no named victim. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-01 07:04 UTC · Ra runread brief →63%0· signal 58
Scientific American, STAT, and SAGE journal building narrative infrastructure. Pipeline: academic study → journalist interviews → major feature. No new adverse events. Trigger event still missing. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-02 07:04 UTC · Ra runread brief →63%0· signal 57
FDA 503B GLP-1 exclusion could push some outsourcing facilities to pivot into peptide compounding; marginal increase in contamination risk if lower-quality facilities enter peptide space. Speculative. No new adverse events. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination; FDA confirms no adverse event spike
- 2026-05-03 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. Partnership for Safe Medicines is new institutional actor in safety narrative — pharma-backed, currently focused on GLP-1s not peptides. Could pivot if PCAC opens peptide compounding. Journalistic templates remain positioned without trigger event. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-04 07:04 UTC · Ra runread brief →63%0· signal 58
NYT David Dodge covering peptides on Glossy podcast confirms journalistic infrastructure building. Beat reporters on podcasts typically precede major features by 2-6 months. SciAm feature adds substrate. But no new adverse events and FDA no-spike finding holds. Dual-direction signals cancel. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-05 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. No new investigative features. Journalistic templates positioned but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-06 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. 503B exclusion rationale disclosed 455+ compounded semaglutide and 320+ compounded tirzepatide adverse events — not peptide-specific but establishes compounding-safety narrative template for post-PCAC media framing. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-07 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. No new investigative features. Journalistic templates positioned but trigger event absent. Dual-direction signals (adoption increases exposure; reclassification reduces contamination) cancel. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-08 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. No new investigative features. Journalistic infrastructure positioned but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-09 07:04 UTC · Ra runread brief →63%0· signal 58
No new top-5 outlet feature. Eric Topol Substack peptide piece is named-voice leading indicator — historically fronts WSJ/NYT health features 6-12 months. ECRI/ISMP joint warning queues clinical-specialist trigger. Discourse build-phase intensifying. Trigger event still absent. Holding.
Counter-narrativeFDA enforcement of gray-market sellers tightens fast enough to prevent headline-grade incident before March 2027
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://erictopol.substack.com/p/the-peptide-craze
- https://theconversation.com/the-peptide-problem-hype-is-outrunning-the-evidence-280715
- 2026-05-10 07:04 UTC · Ra runread brief →63%0· signal 58
No new adverse events. PeptideJournal narrative distortion (Cat 2 removal framed as reclassification) could paradoxically increase gray-market sourcing if consumers misinterpret as full legalization. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated compounders reducing gray-market contamination and headline incident probability
- 2026-05-11 07:04 UTC · Ra runread brief →63%0· signal 58
No new adverse events. No new top-5 outlet features. 30% gray-market contamination rate unchanged. Discourse infrastructure building but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-12 07:04 UTC · Ra runread brief →63%0· signal 58
No new adverse events. No new top-5 outlet features. Gray-market contamination rates unchanged. Discourse infrastructure building but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-13 07:04 UTC · Ra runread brief →63%0· signal 58
No new adverse events. No new top-5 outlet features. Estrogen-patch-shortage pattern (FDA denies shortage while demand doubles) filed as analog for peptide demand-supply dynamics. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated compounders reducing gray-market contamination and headline incident probability
- 2026-05-14 07:04 UTC · Ra runread brief →65%+0.02· signal 60
ISMP and ECRI formal warnings plus LegitScript emerging-risk categorization escalate discourse infrastructure from researcher/media to institutional level. PBS political framing pre-builds backlash scaffold. +0.02 for category escalation without trigger event.
Counter-narrativeCat 1 reclassification channels demand to regulated compounders reducing gray-market contamination and headline incident probability
- https://www.medscape.com/viewarticle/wellness-peptides-lack-reliable-safety-information-watchdog-2026a1000fbf
- https://www.legitscript.com/high-risk-and-problematic-products/peptides-in-dietary-supplements-emerging-risk/
- https://www.pbs.org/newshour/health/fda-to-weigh-easing-limits-on-unproven-peptides-favored-by-rfk-jr-and-maha-supporters
- 2026-05-15 07:04 UTC · Ra runread brief →65%0· signal 60
No new adverse events. BSR Intelligence published institutional-grade peptide industry briefing with counterfeit risk coverage (paywalled). Discourse infrastructure building at institutional level. No trigger event. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-16 07:04 UTC · Ra runread brief →67%+0.02· signal 62
MedicalXpress reports AI methodology scanning 400000 Reddit posts for overlooked GLP-1 side effects — technique transfers directly to compounded peptides. Detection-channel signal: time between anonymous user complaint and citable adverse-event corpus collapsing. Preventive Medicine Daily pharmacovigilance analysis confirms arsenic 10x toxicity limits and lead contamination. +0.02 for detection-methodology institutionalization absent trigger event.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-17 07:04 UTC · Ra runread brief →70%+0.03· signal 67
ProPublica feature is tier-1 institutional safety escalation with 30-90 day documented downstream pickup window into named falsifier outlets. Combined with NPR May 6, UNSW academic paper, TikTok algorithmic suppression of peptide creators, and ProRx 15k-vial sterility recall. Trajectory accelerating. +0.03.
Counter-narrativeIf Cat 1 reclassification successfully channels demand to regulated 503A compounders, gray-market headline risk drops materially; ProPublica adjacent but not formally on the falsifier outlet list (NYT/WSJ/CNN/NPR/WaPo)
- https://www.propublica.org/article/peptide-safety-fda-compounding-pharmacies
- https://www.npr.org/2026/05/06/nx-s1-5812662/medicare-bridge-glp1-drugs-copay
- https://tucson.com/news/nation-world/business/personal-finance/article_780568ec-86c7-5705-9cd5-f2cec1a25276.html
- https://www.unsw.edu.au/newsroom/news/2026/04/injectable-peptides-anti-ageing-trend-safe-humans-evidence
- https://www.tiktok.com/discover/why-peptide-influencers-blocked
- 2026-05-18 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events or top-5 outlet features since yesterday's ProPublica +0.03 adjustment. Institutional safety discourse building at institutional level. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-19 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. JAMA VA study 35% higher NAION risk among GLP-1 users is parallel safety-litigation template for adjacent peptide class. Template signal not trigger. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-20 07:04 UTC · Ra runread brief →70%0· signal 67
BPC-157 at Google Trends peak (100) in April. 281%/459%/412% YoY growth Google/TikTok/Instagram. Discourse infrastructure in late build-phase (ECRI ISMP PBS ProPublica academic papers). Journalistic template complete but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-21 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. AbbVie Alora estrogen patch discontinuation filed as gray-market-template reference class. Template without trigger. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-22 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. BSR Intelligence peptide industry briefing (March-May 2026) confirms elevated counterfeit and contamination risk at baseline. TRIUMPH-1 dysesthesia creates collateral side-effects media frame but not directly peptide-related. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; ProPublica adjacent but not formally on the falsifier outlet list
- 2026-05-23 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Institutional template positioning stable at late build-phase month 2-3. TRIUMPH-1 dysesthesia (Day 2) conditions media genre but is not a trigger for peptide safety specifically. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; TRIUMPH-1 dysesthesia expands side-effects media frame but is branded GLP-1 not compounded peptide
- 2026-05-24 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. FDA confirms no spike from compounded peptides specifically. Institutional template positioning stable at late build-phase. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; 775+ compounded GLP-1 adverse events provide corpus but no peptide-specific named-victim event
- 2026-05-26 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase (ECRI ISMP LegitScript ProPublica PBS Topol). Trigger event absent. Dual-direction signals cancel. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events reported
- 2026-05-27 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. WaPo factory access is dual-use: validates peptide market (bearish) while positioning reporter for future safety investigation (bullish). Signals cancel. Discourse infrastructure stable at late build-phase. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events reported
- 2026-05-28 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. CNN April 2026 coverage is explainer mode not investigation. Discourse infrastructure stable at late build-phase. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events reported
- 2026-05-29 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. USADA BPC-157 prohibition creates doping-scandal angle as potential named-victim catalyst — speculative not probability-moving. Discourse infrastructure stable at late build-phase. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; USADA prohibition creates potential athlete-named-victim catalyst
- 2026-05-30 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-05-31 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. Trigger event absent. 304 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-01 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. Trigger event absent. 303 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-02 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. Trigger event absent. 302 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events reported
- 2026-06-03 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. ADA week absorbs health media oxygen narrowing window for peptide safety features. Post-ADA and pre-PCAC late June is next plausible media window. 301 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-04 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. Precision Peptide 25K Rx/day 503A deal marginally channels demand toward regulated compounding, reducing gray-market exposure. ADA week absorbs health media oxygen. Post-ADA / pre-PCAC late June is next plausible media window. 300 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; Precision Peptide 503A deal confirms channeling thesis
- 2026-06-05 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. ADA week absorbs health media oxygen narrowing window for peptide safety features. Post-ADA pre-PCAC late June is next plausible media window. 299 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-06 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. ADA Day 2 absorbs health media oxygen. Retatrutide TRIUMPH-1 presenting today 1:30 PM CDT — will dominate health news cycle through Monday narrowing window for peptide safety features. Post-ADA pre-PCAC late June remains next plausible media window. 298 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-07 07:04 UTC · Ra runread brief →70%0· signal 67
Weekly review. No new adverse events. ADA absorbed health media bandwidth June 5-8. Post-ADA pre-PCAC late June next plausible media window. ProPublica WaPo templates positioned no trigger event. Stoic: unactionable. 297 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-08 07:04 UTC · Ra runread brief →70%0· signal 67
Weekly review. No new adverse events. ADA concluded June 8 — post-ADA / pre-PCAC media window (June 9 - July 22) now open. Highest-probability period for peptide safety features. Stanford muscle-GLP-1 study bridges GLP-1 and peptide narratives culturally. ProPublica WaPo templates positioned no trigger event. Stoic: unactionable. 296 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-09 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. Post-ADA / pre-PCAC media window (June 9 - July 22) now open — highest-probability period for peptide safety features. Health media bandwidth freed from ADA coverage. PCAC deadline creates editorial urgency. 296 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-10 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. Post-ADA / pre-PCAC media window (June 9-July 22) now in Day 2 — highest-probability period for investigative peptide safety features. Preventive Medicine Daily gray-market pharmacovigilance analysis builds academic substrate. ProPublica WaPo templates positioned but no named-victim trigger event. 295 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-11 07:04 UTC · Ra runread brief →73%+0.03· signal 70
MATERIAL. DOJ criminal enforcement escalating: Tailor Made Compounding $1.79M forfeiture; Dr. Watkins indicted April 2026 selling peptides to 200+ patients; Paradigm Peptides guilty pleas Dec 2025; BioPeptide Labs charged; Peptide Sciences shut down March 2026; 50+ FDA warning letters 2024-2025. Historian: matches EVALI trajectory — DOJ indictments precede top-5 outlet features 3-12 months. Skeptic: charges are misbranding/fraud not patient harm — named-victim catalyst absent. Bayesian: court documents and named defendants provide institutional narrative infrastructure for ProPublica/WaPo templates already positioned. Post-ADA pre-PCAC media window open. +0.03.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but DOJ criminal enforcement creates institutional narrative infrastructure for investigative features even without named-victim catalyst
- https://www.amcdefenselaw.com/justice-watch/peptide-industry-federal-criminal-charges-2026
- https://www.stevenslee.com/health-law-observer-blog/indictment-of-osteopathic-physician-signals-shift-in-peptide-enforcement/
- https://peptidelaws.com/news/recent-doj-actions-against-illegal-peptide-distributors
- https://www.justice.gov/usao-ndin/united-states-v-matthew-kawa
- https://grokipedia.com/page/FDA_Enforcement_Actions_Against_Research_Peptide_Vendors_20252026
- 2026-06-12 07:04 UTC · Ra runread brief →73%0· signal 67
No new adverse events. Post-ADA pre-PCAC media window Day 4 of 44. DOJ enforcement infrastructure continues (Tailor Made Watkins Peptide Sciences). ProPublica WaPo templates positioned no trigger event. PeptideExaminer enforcement timeline confirms 50+ warning letters 2024-2025 with criminal referral escalation. 292 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but DOJ criminal enforcement creates institutional narrative infrastructure for investigative features even without named-victim catalyst
- 2026-06-13 07:04 UTC · Ra runread brief →73%0· signal 67
No new adverse events. Post-ADA pre-PCAC media window Day 5 of 44. NBC estrogen-patch story uses FDA-says-X-patients-say-Y template structurally identical to future peptide safety feature template. Template migration across health-journalism categories is a leading indicator. DOJ court documents (Tailor Made Watkins Peptide Sciences) provide named-defendant infrastructure. 290 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but DOJ criminal enforcement creates institutional narrative infrastructure for investigative features even without named-victim catalyst
- 2026-06-14 07:04 UTC · Ra runread brief →73%0· signal 68
Weekly review. No new adverse events. Nature published peptide craze feature creating academic-to-media citation pipeline. Post-ADA pre-PCAC media window Day 6 of 44. DOJ court documents (Tailor Made Watkins Peptide Sciences 50+ warnings) provide named-defendant infrastructure. TikTok +459% YoY accelerates amateur adoption increasing exposure. Dual-direction signal. 289 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but Nature engagement plus DOJ enforcement infrastructure creates narrative pipeline for investigative features
- https://www.nature.com/articles/d41586-026-01816-x
- https://www.glossy.co/beauty/injectable-peptide-therapy-went-mainstream-in-2025-priming-consumers-for-the-next-big-wave-in-wellness/
- https://www.amcdefenselaw.com/justice-watch/peptide-industry-federal-criminal-charges-2026
- https://www.propublica.org/article/peptide-safety-fda-compounding-pharmacies
- 2026-06-15 07:04 UTC · Ra runread brief →73%0· signal 68
Weekly review. No new adverse events. Lilly warning re fraudulent compounded tirzepatide (bacteria impurities incorrect structures) establishes branded-pharma-documents-contamination template. FDA 455+ semaglutide AERs 320+ tirzepatide AERs on record. Post-ADA pre-PCAC media window Day 7 of 44. 288 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but Lilly contamination warning plus 455+ semaglutide AE reports plus DOJ enforcement creates institutional narrative infrastructure
- 2026-06-16 07:04 UTC · Ra runread brief →73%0· signal 67
No new adverse events. Post-ADA pre-PCAC media window Day 9 of 44. DOJ enforcement infrastructure intact (Tailor Made Watkins Peptide Sciences 50+ warnings). Lilly contamination warning template established. 287 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but DOJ criminal enforcement creates institutional narrative infrastructure for investigative features even without named-victim catalyst
- 2026-06-17 07:04 UTC · Ra runread brief →73%0· signal 67
No new adverse events. LegitScript flagged peptides in supplements as emerging risk — compliance platform classifications cascade to Google Ads Facebook Visa/Mastercard policy. PBS frames PCAC as political. Post-ADA pre-PCAC media window Day 10 of 44. DOJ enforcement infrastructure intact. 286 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but LegitScript emerging-risk classification plus PBS political framing creates institutional narrative infrastructure for investigative features
- https://www.legitscript.com/high-risk-and-problematic-products/peptides-in-dietary-supplements-emerging-risk/
- https://www.pbs.org/newshour/health/fda-to-weigh-easing-limits-on-unproven-peptides-favored-by-rfk-jr-and-maha-supporters
- https://www.peptidedeck.com/blog/are-peptides-safe-2026-mainstream-science-review
- 2026-06-18 07:04 UTC · Ra runread brief →75%+0.02· signal 70
Chainalysis quantifies gray-market peptide economy at $100M+ annual run rate Q1 2026 $32M +159% QoQ. Fortune identifies looksmaxxing demographic young males buying via crypto zero medical supervision. Bloomberg gold rush feature. Structural analog to EVALI vaping demographic pattern. Higher-risk population expands contamination exposure base rate. Moving +0.02 to 0.75. 285 days to resolution.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but $100M+ crypto gray-market with looksmaxxing demographic expands unregulated exposure faster than regulatory channel shift
- 2026-06-19 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. ECRI and ISMP joint white paper (May 2026) now fully surfaced: two most credible US patient safety watchdogs formally warning that compounded peptide market has outpaced safety data. BPC-157 35/36 studies in animals; gray-market purity 5-75% with arsenic and lead. These are the SAME organizations that flagged compounding risks pre-NECC 2012. Creates formal we-warned-you timestamp for investigative journalism. Signal partially priced yesterday via Medscape search result; institutional provenance is the new data point. 284 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but ECRI/ISMP institutional warning plus $100M+ crypto gray-market with looksmaxxing demographic expands unregulated exposure faster than regulatory channel shift
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://home.ecri.org/blogs/ecri-news/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn
- https://www.medscape.com/viewarticle/wellness-peptides-lack-reliable-safety-information-watchdog-2026a1000fbf
- 2026-06-20 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. ECRI/ISMP and Chainalysis gray-market fully priced. Post-ADA pre-PCAC media window Day 13 of 44. 503B comment-period deadline June 29 may trigger media round-up on compounding safety. DOJ enforcement infrastructure intact. 283 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but ECRI/ISMP institutional warning plus $100M+ crypto gray-market with looksmaxxing demographic expands unregulated exposure faster than regulatory channel shift
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- https://www.bloomberg.com/features/2026-peptide-legalization-gold-rush/
- 2026-06-21 07:04 UTC · Ra runread brief →75%0· signal 70
Weekly review. No new adverse events. Chainalysis deeper-read details: Chinese manufacturers pivoted from fentanyl and amphetamine precursors to peptide production — same supply chain that fueled opioid crisis now producing injectables. Per-buyer testing expenditure dropped 88% ($67 to $8) consumers injecting untested products. Refinements of already-priced June 18 data not independent signals. Post-ADA pre-PCAC media window Day 14 of 44. 503B comment deadline June 29 may trigger media round-up. 282 days to resolution.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but fentanyl-precursor supply chain pivot to peptide manufacturing plus 88% per-buyer testing expenditure collapse expands unregulated exposure
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- https://www.chainalysis.com/blog/gray-market-peptide-crypto-boom/
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- 2026-06-22 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. 503B comment deadline June 29 in 7 days — FDA press release cites 455+ adverse events from compounded semaglutide and 320+ from compounded tirzepatide. Comment-period coverage may spill over to peptide safety narrative. ECRI/ISMP and Chainalysis fully priced. Post-ADA pre-PCAC media window Day 15 of 44. 281 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but fentanyl-precursor supply chain pivot plus 88% per-buyer testing expenditure collapse expands unregulated exposure
- https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- 2026-06-23 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. 503B comment deadline June 29 in 6 days — comment-period coverage may spill into peptide safety narrative. Peptide Sciences voluntary shutdown (March 2026) removed one major gray-market vendor but scatter-effects demand to remaining sellers. ECRI/ISMP and Chainalysis fully priced. Post-ADA pre-PCAC media window Day 16 of 44. 280 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but fentanyl-precursor supply chain pivot plus 88% per-buyer testing expenditure collapse expands unregulated exposure faster than regulatory channel shift
- https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://peptidesexplorer.com/blog/peptide-sciences-shut-down
- 2026-06-24 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Cumulative compounded GLP-1 adverse events 775+ (455 semaglutide + 320 tirzepatide) — consolidation of prior figures not new disclosure. Post-ADA pre-PCAC media window Day 17 of 44. 503B comment-period close June 29 may trigger safety-adjacent coverage. ECRI/ISMP and Chainalysis fully priced. 279 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but fentanyl-precursor supply chain pivot plus 88% per-buyer testing expenditure collapse expands unregulated exposure faster than regulatory channel shift
- https://www.peptidejournal.org/legal/fda-peptide-regulation-complete-2025-2026-timeline
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- 2026-06-25 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 18 of 44. 503B comment-period close June 29 in 4 days — FDA proposal cites cumulative 775+ compounded GLP-1 adverse events. Comment-period coverage may spill into broader compounding safety narrative. ECRI/ISMP and Chainalysis fully priced. 278 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but 503B comment-period close June 29 citing 455+ semaglutide AERs 320+ tirzepatide AERs may trigger safety-adjacent coverage
- https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12927500/
- 2026-06-26 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 19 of 44. 503B comment-period close June 29 in 3 days. PeptideDeck safety review and Pharmacy Times coverage joining the institutional-concern content layer but adding no new data points. ECRI/ISMP and Chainalysis fully priced. 277 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but 503B comment-period close June 29 citing 775+ compounded GLP-1 adverse events may trigger safety-adjacent coverage amplifying broader compounding scrutiny
- https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://www.peptidedeck.com/blog/are-peptides-safe-2026-mainstream-science-review
- 2026-06-27 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 20 of 44. 503B comment-period EXTENDED to July 30 (from June 29). This concentrates two compounding-safety media events — PCAC July 23-24 and 503B close July 30 — into a single week rather than spreading across June-July. May amplify safety-adjacent coverage. ECRI/ISMP and Chainalysis fully priced. 276 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but 503B extension to July 30 concentrates PCAC and 503B-close media events into single week amplifying safety-adjacent coverage
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- 2026-06-28 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 21 of 44. 503B extension to July 30 creates calendar concentration: PCAC July 23-24 and 503B close July 30 within same week. Two compounding-safety media events in 7 days creates amplification structure for investigative coverage. Lilly fraudulent tirzepatide warning and FDA 775+ adverse event citation remain shelf-ready for journalists. 275 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but 503B-PCAC same-week concentration July 23-30 amplifies compounding safety media coverage
- https://www.pharmexec.com/view/federal-judge-blocks-rfk-vaccine-advisory-council-appointments
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- https://sherwood.news/culture/the-peptide-gold-rush-how-impending-deregulation-could-supercharge-a-shadow/
- 2026-06-29 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 22 of 44. PCAC-503B concentration week July 23-30 creates amplification structure. FDA 80+ telehealth warning letters plus Gram Peptides warning March 2026 provide shelf-ready journalist material. 274 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- 2026-06-30 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. PCAC oral presentation deadline today — filing volume signals advocacy intensity and media attention. PCAC-503B concentration week July 23-30 creates dual-hook amplification for investigative journalism. 30% contamination rate from independent testing confirmed by BSCG and multiple clinic sources. 273 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-01 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Bridge launch creates latent narrative hook: Medicare covers GLP-1s at $50 but not peptides — potential media angle for why patients turn to gray market. PCAC-503B concentration week July 23-30 creates dual-hook amplification. 272 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-02 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 25 of 44. PCAC-503B concentration week July 23-30 creates dual-hook amplification. Estrogen patch shortage 44% fill difficulty across 8000 women validates supply-shortage-to-gray-market pipeline pattern applicable to peptides. 271 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-03 07:04 UTC · Ra runread brief →75%0· signal 70
No new US adverse events. Medsafe NZ issued consumer advisory May 21 2026 warning about significant health and legal risks of unapproved peptide products — international regulatory bodies now publicly flagging safety adding journalistic basis for US investigative coverage. PCAC-503B concentration week July 23-30 creates dual-hook amplification structure. 270 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-04 07:04 UTC · Ra runread brief →75%0· signal 70
No new US adverse events. July 4 holiday. PCAC-503B concentration week in 19 days creates dual-hook editorial structure. Medsafe NZ advisory continues providing international regulatory precedent. 269 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-05 07:04 UTC · Ra runread brief →75%0· signal 72
PCAC conflict-of-interest narrative (AP NBC NPR) creates pre-built editorial framework for peptide safety investigative journalism. FDA staff briefing citing insufficient safety data provides source material. PCAC-503B concentration week July 23-30 creates dual-hook editorial calendar. No new US adverse events. 268 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative may exhaust media appetite for peptide coverage reducing safety-incident likelihood
- 2026-07-06 07:04 UTC · Ra runread brief →75%0· signal 72
FDA warning letter to Gram Peptides March 31 2026 adds concrete enforcement action to investigative-journalism source material. PCAC-503B concentration week July 23-30 creates dual-hook editorial calendar. Medsafe NZ advisory provides international precedent. No new US adverse events. 267 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative exhausts media appetite for peptide coverage
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- https://abcnews.com/Health/wireStory/fda-panel-peptides-include-experts-promote-unproven-chemicals-134321957
- https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
- 2026-07-07 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events; post-ADA pre-PCAC media window day 30 of 44; STAT conflict-of-interest article is institutional narrative infrastructure but not a safety incident; PCAC-503B calendar concentration July 23-30 remains amplification structure; 267 days to resolution; holding 0.75
Counter-narrativeIf PCAC recommends Cat 1 for any peptides the resulting demand surge through regulated channels may paradoxically reduce safety incidents by channeling users away from gray-market sources
- 2026-07-08 07:04 UTC · Ra runread brief →75%0· signal 72
775+ cumulative compounded peptide/GLP-1 adverse event reports; no new headline-grade incident; PCAC meeting July 23 may serve as editorial hook for safety journalism — FDA briefing materials cite 40% contamination rate; PCAC-503B concentration week July 23-30 remains amplification window; 266 days to resolution; holding 0.75
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative may exhaust media appetite for peptide safety coverage
- 2026-07-10 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. PCAC-503B concentration week July 23-30 in 13 days creates dual-hook editorial window. 775+ cumulative AE reports. FDA briefing materials citing 40% contamination rate available to journalists covering hearing. 264 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative may exhaust media appetite for safety coverage
- 2026-07-11 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. PCAC-503B concentration week July 23-30 in 12 days creates dual-hook editorial window. 775+ cumulative AE reports. FDA briefing materials citing 40% contamination available to journalists. 263 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative may exhaust media appetite for safety coverage
- 2026-07-12 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Independent analysis confirms 30% grey-market contamination rate. PCAC week July 23-30 creates dual-hook editorial window for journalists encountering 40% contamination and 775+ AE in briefing materials. 263 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC week editorial window may exhaust media appetite
- 2026-07-13 07:04 UTC · Ra runread brief →75%0· signal 72
FDA briefing docs now public citing 40% contamination and unassessed immunogenicity accessible to journalists. Bloomberg peptide-startup-race amplifies media attention. PCAC week July 23-30 dual-hook editorial window. No new US adverse events. 262 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; media attention fatigue from PCAC cycle may exhaust safety-story appetite
- 2026-07-14 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Regulatory convergence week July 23-30 PCAC plus 503B deadline concentrates media attention on compounding safety. FDA briefing docs with 40% contamination accessible to journalists. 260 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-15 07:04 UTC · Ra runread brief →75%0· signal 72
PSM formal filing adds institutional-grade source material to public record: FDA warning letters to Chinese API producers for sterility violations TB-500 tumor acceleration data 78% complications linked to contamination. Citation-ready for journalists covering PCAC week. No new US adverse events. 259 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-16 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Hims consumer peptide campaign increases mainstream awareness and journalist attention surface. Regulatory convergence week July 23-30 PCAC plus 503B deadline. PSM citation-ready filing accessible. 258 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; Hims consumer campaign may paradoxically increase journalism surface area
- https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60225352/hims-hers-healths-peptide-opportunity-tempered-by-fda-recommendation-says-analyst
- https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
- https://stocktwits.com/news-articles/markets/equity/hims-peptides-campaign-key-fda-meeting/cZmzKDjR7oN
- 2026-07-17 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Regulatory convergence week July 23-30 creates concentrated editorial window. PSM citation-ready filing accessible. FDA briefing docs with 40% contamination. 257 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-18 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Regulatory convergence week July 23-30 creates concentrated editorial window. PSM citation-ready filing with 78% complications linked to contamination. FDA briefing docs with 40% contamination. 256 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-19 07:04 UTC · Ra runread brief →75%0· signal 72
FDA May 2026 import alert on 38 foreign API manufacturers following 14-month MedWatch investigation Q3 2025-Q1 2026 confirmed. Hangzhou Yiqi warning letter April 2026. PSM cites 78% complications linked to contamination. Regulatory convergence week July 23-30 concentrates editorial attention. No top-5 outlet major feature yet. 255 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-20 07:04 UTC · Ra runread brief →75%0· signal 72
FDA background materials cite insufficient safety data plus unassessed immunogenicity across all 7 — citation-ready ammunition for an investigative feature during the July 23-30 convergence week. No top-5 outlet feature yet. 254 days to resolution. Holding.
Counter-narrativeCat 1 denials channel demand toward regulated compounders and the PCAC convergence week may exhaust safety-story appetite before a top-5 feature lands
- 2026-07-21 07:04 UTC · Ra runread brief →75%0· signal 74
Concrete new ammunition: FDA FAERS records a life-threatening incident and a hospitalization linked to BPC-157 contamination; April 2026 Hangzhou Yiqi warning letter/import alert; independent testing found some batches <50% labeled compound. Combined with FDA background materials citing unassessed immunogenicity across all 7, this is citation-ready for an investigative feature during the July 23-30 convergence week. No top-5 outlet feature yet. 253 days to resolution. Holding.
Counter-narrativeA Cat 1 grant channeling demand to regulated 503A compounders plus convergence-week story fatigue could still delay a top-5 feature past March 2027
- 2026-07-22 07:04 UTC · Ra runread brief →75%0· signal 74
Forbes July 21 growing-public-health-challenge piece adds a fresh skeptical Tier-2 feature but is not a top-5 outlet. FAERS BPC-157 contamination + convergence week July 23-30 concentrate editorial attention; no top-5 major feature yet. 252 days to resolution. Holding.
Counter-narrativeA Cat 1 grant channeling demand to regulated 503A compounders plus convergence-week story fatigue could delay a top-5 outlet feature past March 2027.
- https://www.forbes.com/sites/omerawan/2026/07/21/fdas-review-of-peptides-signals-a-growing-public-health-challenge--separating-science-from-hype/
- https://www.safemedicines.org/2026/07/five-reasons-bulk-peptides.html
- https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/
- 2026-07-23 04:05 UTC · Ra runread brief →75%0· signal 74
Convergence-week coverage intensifying (Fortune Jul 20, Forbes Jul 21, NPR-affiliate WWNO Jul 22) but still no top-5 national investigative feature on injuries/contamination/deaths. FAERS BPC-157 hospitalization + Apr 2026 import alerts remain citation-ready. 252 days to resolution. Holding.
Counter-narrativeCat 1 denials channel demand to regulated 503A compounders and convergence-week fatigue could delay a top-5 injury feature past March 2027.
- https://www.wwno.org/npr-news/2026-07-22/peptides-get-their-regulatory-closeup
- https://fortune.com/2026/07/20/the-fda-peptide-vote-could-create-telehealths-next-multibillion-dollar-market-telehealth-hims-ro-glp1-ozempic-injectables/
- https://www.forbes.com/sites/omerawan/2026/07/21/fdas-review-of-peptides-signals-a-growing-public-health-challenge--separating-science-from-hype/
- 2026-07-24 04:04 UTC · Ra runread brief →75%0· signal 76
Vote generated a Tier-1 coverage wave (STAT/Time/Hill/ABC) flagging FAERS BPC-157 adverse events, but still no top-5 national injury/contamination feature; legitimization cuts both ways. Hold 0.75, 250 days out.
Counter-narrativeLegitimization could route demand to regulated 503A compounders with better QC, reducing gray-market incident risk even as overall exposure rises.
- https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
- https://time.com/article/2026/07/23/fda-committee-peptides/
- https://thehill.com/homenews/5987510-fda-committee-votes-peptides/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-25 04:04 UTC · Ra runread brief →75%0· signal 76
Convergence-week coverage continues (TechTimes gray-market legal-limbo Jul 23, Regenexx contamination explainer surfacing endotoxin/heavy-metal/<50%-label findings) but still no top-5 national injury/contamination/deaths feature. FAERS BPC-157 adverse events remain citation-ready. 249 days to resolution. Holding.
Counter-narrativeLegitimization could route demand to regulated 503A compounders with better QC, muting gray-market incident risk even as overall exposure rises.
- https://www.techtimes.com/articles/321365/20260723/gray-market-peptide-users-face-legal-limbo-fda-scientists-oppose-bpc-157-vote.htm
- https://newregenortho.com/the-hidden-risks-of-bpc%E2%80%91157-what-patients-need-to-know-about-contamination-and-safety/
- https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html
- 2026-07-26 04:04 UTC · Ra runread brief →75%0· signal 76
Held. Documented harm rising (43% lab-failure per Janoshik/thepeptidelist; FDA warning letters citing life-threatening infections; Forbes growing-public-health-challenge) but still no top-5 outlet injury/contamination/death feature; NPR covered the vote, not injuries. 248 days out. Loosening cuts both ways (fewer gray-market vs more mainstream users) -- net neutral.
Counter-narrativePCAC loosening channels demand to regulated 503A compounders, potentially reducing gray-market contamination and the injury-feature trigger; convergence-week attention may exhaust editorial appetite.
- 2026-07-27 04:15 UTC · Ra run· flaggedread brief →90%+0.15· signal 88
Material: WaPo published a July 24 investigation (states scrambling to protect consumers; gaping regulatory holes for medspas/peptides) -- a top-5 named outlet -- alongside NYT rebuke-of-FDA-scientists coverage, NBC Washington 30%-of-vials contamination lab finding, and Fortune endotoxin piece. Moves 0.75->0.90. FLAGGED for operator: verify the WaPo investigation qualifies against the injuries/contamination/deaths criteria; if yes resolve TRUE, ~8mo before the 2027-03-31 horizon.
Counter-narrativeThe WaPo piece frames the peptide boom as a regulatory-holes/consumer-protection investigation rather than a narrow injuries/deaths feature, so the operator may judge it short of the injuries/contamination/deaths bar.
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- https://www.usnews.com/news/health-news/articles/2026-07-24/fda-advisers-dismiss-safety-warnings-back-four-peptide-treatments
- https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/
- https://fortune.com/2026/07/23/peptides-endotoxin-contamination-fda-panel-conflicts/
- 2026-07-28 04:05 UTC · Ra run· flaggedread brief →90%0· signal 88
Held 0.90. Verification confirms the WaPo July 24 piece is a systemic regulatory-holes/consumer-protection investigation (states scrambling; medspas under-inspected; peptides unstudied) rather than a narrow injuries/contamination/deaths feature; no NEW top-5 injury feature landed today. Standing operator-verify flag persists: if the WaPo investigation clears the injuries/contamination/deaths bar resolve TRUE ~8mo early (Brier 0.01); if judged short, contamination base rates keep a qualifying feature highly likely before 2027-03-31. Augur note: WaPo spun up a wp-intelligence peptide-beat brief same day, raising odds of a follow-on injuries-specific feature. 246 days to horizon.
Counter-narrativeLegitimization routes demand to regulated 503A compounders with better QC, and the WaPo regulatory-holes framing may be judged short of the injuries/contamination/deaths bar with editorial appetite exhausted post-convergence-week.
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- https://www.washingtonpost.com/wp-intelligence/health-brief/2026/07/24/health-brief-peptide-boom-outpaces-regulators/
- https://www.npr.org/2026/07/22/nx-s1-5902329/peptides-fda-compounding
- https://www.usnews.com/news/health-news/articles/2026-07-24/fda-advisers-dismiss-safety-warnings-back-four-peptide-treatments
- 2026-07-29 04:20 UTC · Ra runread brief →87%-0.03· signal 86
Trimmed 0.90 to 0.87 on a previously-unlogged deflator. ProPublica documented two women intubated after peptide injections at RAADFest (Jul 2025) and Nevada Pharmacy Board fines (Mar 2026); that raw material has been public ~12 months and no top-5 outlet ran the injuries feature even through the Jul 23-24 vote cycle, when WaPo chose the regulatory-holes frame instead. Nevada board could not obtain the product to test, so no causal case series exists. Offsetting: forecast wording is disjunctive (injuries OR contamination OR deaths), the NBC 30%-of-vials lab finding shows the contamination leg is live at national scale, WaPo has a standing peptide beat, and 245 days remain. Skeptic ~0.78 vs Bayesian 0.87 = 0.09, under threshold; mechanical flag clears but the standing operator decision on the WaPo Jul 24 investigation remains OPEN.
Counter-narrativeThe prestige-press frame for peptides is systemic-regulatory, not injuries-narrative -- a documented near-fatal injury cluster has sat unused for 12 months, and no causal case series exists because the product was never recovered for testing.
- https://www.propublica.org/article/peptide-injections-raadfest-rfk-jr
- https://www.propublica.org/article/raadfest-peptide-injections-nevada-fines
- https://www.mmm-online.com/news/raadfest-peptide-injections-nevada-fines/
- https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/
- 2026-07-30 04:10 UTC · Ra runread brief →87%0· signal 86
Held 0.87 deliberately. Two candidate deflators examined and both declined. (1) Reason's Jul 27 gray-market-is-here / FDA-catching-up piece is another outlet choosing the regulatory frame over the injury frame -- but that is yesterday's ProPublica insight recounted, not new information, and pricing the same insight twice on consecutive days is the exact anchoring-drift failure Ra exists to catch. (2) NEW to this forecast's evidence set: FDA closed the research-use-only loophole with seven warning letters all dated Mar 31 2026 (issued Apr 7), incl. Gram Peptides MARCS-CMS 721806 citing retatrutide/tirzepatide plus bacteriostatic-water bundling as evidence of injection intent, and holding that RUO disclaimers do not matter when product pages describe weight loss. That is the Skeptic's named falsifier partially materializing -- but the NBC 30%-of-vials and WaPo findings POSTDATE April, direct evidence the enforcement wave did not clean the market, and historical case F3 says FDA letters without injunction rarely change market state. Net neutral. Skeptic ~0.78 vs Bayesian 0.87 = 0.09, under threshold. Standing operator decision on the WaPo Jul 24 investigation is now day 6 OPEN. 244 days to horizon.
Counter-narrativeThe prestige-press frame remains systemic-regulatory rather than injuries-narrative, and FDA enforcement against research-use-only gray-market sellers is the Skeptic's named falsifier partially materializing.
- https://reason.com/2026/07/27/the-peptide-gray-market-is-already-here-the-fda-is-just-catching-up/
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- https://policycanary.io/blog/fda-research-peptide-warning-letters-april-2026
- https://www.safemedicines.org/2026/07/five-reasons-bulk-peptides.html
- 2026-07-31 04:15 UTC · Ra runread brief →85%-0.02· signal 85
Moved on a primary source rather than a media frame. openFDA drug enforcement contains exactly TWO peptide recalls in the whole database, both GenoGenix LLC of Boca Raton FL (GHK-Cu for injection D-0051-2026 and a peptide reconstitution solution D-0076-2026), both Class II lack-of-sterility, both initiated 2025-07-30, neither injury-driven. The documentary spine an injuries-feature would rest on is thinner than the coverage volume implies. Distinct evidence class from the last two days frame reading, so not double-pricing. WaPo resolution decision now day 7 open.
Counter-narrativeThe forecast wording covers injuries, contamination OR deaths, and the 30-percent-of-vials lab finding plus the WaPo investigation are already contamination coverage in a top-5 outlet, so a thin recall record may bound the wrong branch of the disjunction.
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22 (openFDA, 2 results total)
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/
- 2026-08-01 04:12 UTC · Ra runread brief →85%0· signal 84
Held 0.85 on no new evidence. A sweep for NYT, WSJ, CNN and NPR peptide-safety features returned nothing newer than WaPo July 24; the only fresh Federal Register peptide items since July 24 are two NIH invention-licensing notices and one product-specific-guidance availability notice, none of them safety. The live question on this forecast is no longer its probability, it is the operator resolution decision on whether WaPo July 24 already satisfies it, now DAY 8 open. Signal strength 85 to 84: a day of no new coverage is mild decay, not a reprice.
Counter-narrativeIf the operator rules the WaPo July 24 investigation a regulatory-systems story rather than an injuries-contamination-deaths feature, the forecast needs a genuinely new top-5 feature within eight months and today produced none.
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=peptide&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-24 (count 3, none safety or 503A)
- https://fortune.com/2026/07/23/peptides-endotoxin-contamination-fda-panel-conflicts/
- https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/
- 2026-08-02 04:15 UTC · Ra runread brief →85%0· signal 85
Held. No new candidate feature since WaPo July 24. The one new primary-source read cuts against the forecast's causal premise rather than its outcome: openFDA drug enforcement returns two peptide records in total. Further probability work on this row is low value until the operator supplies the major-feature rubric; day 9 open.
Counter-narrativeThe federal enforcement record carries exactly two peptide recalls, both from one Florida firm and both initiated July 2025, so the injury-attribution trail a top-five outlet needs for an injuries feature is thinner than the 40-percent-contamination premise implies.
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=10 (openFDA, total 2, last_updated 2026-07-22, both GenoGenix LLC Class II sterility, one of them GHK-Cu for Injection)
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- https://fortune.com/2026/07/23/peptides-endotoxin-contamination-fda-panel-conflicts/
- https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/
- 2026-08-03 04:15 UTC · Ra runread brief →85%0· signal 85
Held. Two independent openFDA queries today: product_description returns the same two GenoGenix records as 2026-08-02, reason_for_recall returns zero. Ten days after the WaPo investigation the enforcement trail is unchanged, which is a real negative check rather than an absence of looking. No new top-five candidate feature in August. Probability work stays low-value until the operator supplies the major-feature rubric; day 10 open.
Counter-narrativeThe federal enforcement record has not moved at all in the ten days since the Washington Post investigation, so the injury-attribution trail a top-five outlet needs for an injuries feature is thinner than the 40-percent-contamination premise implies.
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=10 (openFDA HTTP 200, total still exactly 2, last_updated 2026-07-22, both GenoGenix LLC Class II sterility, recall_initiation_date 20250730)
- https://api.fda.gov/drug/enforcement.json?search=reason_for_recall:%22peptide%22 (HTTP 404 NOT_FOUND, zero records)
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- WebSearch sweep of NYT/WSJ/CNN/NPR for an August peptide injuries feature returned none
- 2026-08-04 04:15 UTC · Ra runread brief →85%0· signal 85
Held. Today's negative is strictly harder than yesterday's: the openFDA enforcement endpoint did not merely return the same two records, its own last_updated advanced a week, so the dataset was rebuilt and added nothing. Horizon is 2027-03-31, 239 days out, so twelve quiet days barely bear on it. Day 11 open on the resolution decision and the blocker is still a one-line operator rubric, not evidence.
Counter-narrativeThe enforcement dataset refreshed on 2026-07-29 and still carries exactly two peptide recalls, both initiated in July 2025, so twelve days after the Washington Post investigation there is still no federal injury trail for a second top-five outlet to follow.
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=10 (agent-fetch run 30876911527, HTTP 200, total still exactly 2, both GenoGenix LLC Class II sterility, recall_initiation_date 20250730 - but meta.last_updated moved 2026-07-22 to 2026-07-29, so the enforcement dataset refreshed inside the window and added zero peptide records)
- WebSearch sweep NYT/WSJ/CNN/NPR/WaPo for an August peptide injuries feature returned none; the only new contamination coverage is NBC Washington on the 30-percent-of-vials lab finding, an NBC owned-and-operated station and not on this forecast's top-five list
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- 2026-08-05 04:15 UTC · Ra runread brief →81%-0.04· signal 82
Attention was the assumed catalyst and attention arrived. At the single highest-salience moment this category will have - NPR's own words are 'unprecedented attention' - a listed outlet assigned a health reporter and produced an explainer about rulemaking, not about injuries. That reframes the binding constraint: it is not media appetite, which is now demonstrably maxed, it is the absence of a documented injury trail, and that trail has been measurably static for four months of Ra runs (two GenoGenix sterility recalls, both initiated 2025-07-30, dataset rebuilt 2026-07-29 adding none). Day 12 of the open operator rubric decision.
Counter-narrativeThe harm feature is a 238-day question, not an August question: NPR now has a named reporter on the peptide beat at a listed outlet, which is the mechanism by which the follow-up harm story gets assigned, and the WaPo 2026-07-24 investigation may already satisfy the threshold under an operator rubric that does not yet exist.
- https://www.npr.org/2026/08/03/nx-s1-5913381/health-fda-peptides-product-regulation (agent-fetch run 30974432502, HTTP 200, 159,668 bytes: NPR, one of the forecast's five named outlets, published 'What would it take to get peptides on the shelf?' on 2026-08-03 07:00 ET, All Things Considered, 3:52 segment plus transcript, by Will Stone - and it is a REGULATORY-PATHWAY piece, not an injuries/contamination/deaths feature; verbatim: 'It's still illegal for pharmacies in the U.S. to make these compounds')
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=10 (same run, HTTP 200, total still exactly 2, both GenoGenix LLC Class II 'Lack of Assurance of Sterility', recall_initiation_date 20250730, meta.last_updated held at 2026-07-29)
- 2026-08-06 04:15 UTC · Ra runread brief →89%+0.08· signal 88
The injury trail that yesterday named as the binding constraint arrived inside 48 hours, and it arrived with a court record, a 70-month sentence, an adulteration finding and a named victim on camera. Reference class - NECC 2012, the compounded-semaglutide adverse-event wave, the 2024 med-spa botulism cluster - says the top-tier feature follows a named victim plus a court record rather than raw adverse-event counts. Two private accreditation bodies launching in July is the industry-self-regulation counter-narrative and it is real, but it reads as a paragraph inside the feature rather than a suppressor of it. Would be 0.93 if the forecast were not restricted to five named outlets. Rubric decision day 13.
Counter-narrativeThe forecast names exactly five outlets and the outlet that ran this hardest is CBS, which is not one of them; WaPo already published its state-oversight investigation on 2026-07-24 and an editor who just ran the peptide beat may consider it covered for a quarter.
- https://www.safemedicines.org/2026/08/august-3-2026.html (agent-fetch run 31070744390, HTTP 200, 97910 bytes: Partnership for Safe Medicines digest dated 2026-08-03 - a federal judge sentenced the owner of a peptide company to 70 months in prison after a guilty plea to selling unapproved drugs and illegally importing them; prosecutors said the products were falsely marketed as high-purity US-made research chemicals using forged laboratory certificates; some were adulterated with testosterone, causing severe adverse effects including a case of steroid-induced psychosis; described as one of the first major criminal prosecutions in the research-use-only peptide market; same digest carries Texas murder charges against a physician and med-spa owner over a 2023 IV death, NABP model legislation letting pharmacy boards license peptide-handling facilities, and a Health Canada permanent injunction against Canlab Research)
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=10 (agent-fetch run 31070681710, HTTP 200, total still exactly 2, both GenoGenix LLC Class II Lack of Assurance of Sterility, recall_initiation_date 20250730, meta.last_updated holding at 2026-07-29 - one of the two is GHK-Cu Copper Peptide for Injection)
- WebSearch routing only: CBS News and CBS Mornings carried the sentencing; CBS is NOT one of the forecast's five named outlets
- 2026-08-07 04:15 UTC · Ra runread brief →91%+0.02· signal 90
Small move on a large day, deliberately. A named firm, named lots and reported injuries across three states is the hook a top-five feature gets built on and there are 236 days left to build it, so +0.02; but the honest read is that the probability is no longer the interesting number, because WaPo already published a peptide-contamination investigation on 2026-07-24 and whether it counts is an operator rubric decision now on day 14.
Counter-narrativeThe forecast names five outlets and requires a major feature, and neither the San Antonio Express-News nor HuffPost is one of them, so today's evidence raises the base rate of the event without touching the binding constraint - and the same category-for-entity substitution cost 0.18 on bpc157-pcac-2026 two weeks ago.
- https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/victory-medical-center-pharmacy-issues-voluntary-nationwide-recall-certain-lots-compounded (identified by WebSearch, NOT fetched - fda.gov blocks GitHub runners at the IP layer; corroborated by two independent secondary items in data/news/2026-08-07.json dated 2026-08-06, San Antonio Express-News 'Texas pharmacy recalls injectable peptides over life-threatening endotoxin risk' and Medical Daily 'Texas Pharmacy Recalls Compounded Glutathione Vials After Patients Report Fever Chills and Racing Heartbeat': Victory Medical Center Pharmacy of Austin TX recalled three lots of compounded glutathione 200 mg/mL multi-dose vials for elevated bacterial endotoxin with adverse events already reported)
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=20 (agent-fetch run 31146638435, HTTP 200: total still exactly 2, both GenoGenix LLC, D-0051-2026 and D-0076-2026, and meta.last_updated is 2026-07-29)
- https://api.fda.gov/drug/enforcement.json?search=state:%22TX%22+AND+report_date:%5B20260715+TO+20260831%5D&limit=30 (same run, HTTP 200: total 3, ChloraPrep El Paso, Medline Dallas, QuVa Sugar Land - none is Victory Medical, so openFDA is nine days stale and its silence is not a negative)
- data/news/2026-08-07.json gnews-compounding (Tier 0 on disk: HuffPost 2026-08-06 'Unregulated Peptides Are Truly The Wild West Right Now')
- 2026-08-08 04:15 UTC · Ra runread brief →92%+0.01· signal 91
Fifth consecutive day of broadening safety coverage and the first day the legal trade press joins it, but the forecast names NYT, WSJ, CNN, NPR and WaPo and today added none of them. +0.01 for accumulating hooks over 235 remaining days. The number is no longer the interesting question: WaPo published a peptide-contamination investigation on 2026-07-24 and the operator rubric decision on whether it qualifies is now on day 15.
Counter-narrativeNone of today's five safety items is from one of the five named outlets, so the category coverage keeps thickening while the specific binding condition is untouched - the same category-for-entity error that cost 0.49 on bpc157-pcac-2026.
- data/news/2026-08-07.json gnews-peptides and gnews-compounding (Tier 0 on disk): HuffPost 2026-08-06 'Unregulated Peptides Are Truly The Wild West Right Now - And The FDA's Next Decision Could Have Severe Consequences'; The Conversation 2026-08-07 'DIY peptide injections are risky, and people may make serious mistakes when administering them'; Longevity LIVE 2026-08-07 'Peptides Are Having a Moment. Most Buyers Have No Idea What They're Injecting.'; GoodRx 2026-08-06 'Are Peptides Safe? Potential Risks to Consider'; Latham & Watkins 2026-08-06 'FDA on Peptides: A New Landscape for Compounders'
- the Victory Medical Center Pharmacy compounded-glutathione endotoxin recall carried forward from the 2026-08-07 run, still UNVERIFIED at fda.gov
- 2026-08-09 04:18 UTC · Ra runread brief →92%0· signal 90
Held at 0.92 and the ratchet stops here. Five consecutive runs added +0.01 or +0.02 each on category coverage thickening while the counter_narrative field said every time that category is not entity; today the number is unchanged but its basis is rebuilt. Decomposed rather than nudged: P(the WaPo 2026-07-24 investigation qualifies under the operator rubric) about 0.80, and if it does not, P(another top-five feature inside 235 days) about 0.60 given twelve months of very rich hooks produced exactly one, so 0.80 + 0.20*0.60 = 0.92. The 0.80 is the load-bearing assumption and it is an operator rubric call now on day 16, not a forecasting question. STEP V caught the ProPublica date before it was written as new evidence: a CLASS=DATE defect avoided.
Counter-narrativeThe ProPublica piece is the reference class arguing against me, not for me: the archetypal hook - two named hospitalisations, ventilators, an unlicensed-in-state physician, two active state investigations, an HHS-secretary angle - landed in July 2025 and the five named outlets did not run the feature for twelve months.
- https://www.propublica.org/article/peptide-injections-raadfest-rfk-jr (agent-fetch run 31294151586, HTTP 200, 292099 bytes: ProPublica investigation into two women hospitalised in critical condition on ventilators after peptide injections at a booth run by a California-licensed physician not licensed in Nevada, at RAADFest in Las Vegas, with the Southern Nevada Health District and the Nevada Board of Pharmacy both investigating and an RFK Jr framing - BYLINE DATE IS 2025-07-29, thirteen months old, NOT a new August 2026 item as the search engine surfaced it)
- Tier 0 on disk: a jq sweep of the last seven data/news digests for nytimes, wall street journal, wsj, cnn, npr and washington post returned ZERO items, sixth consecutive day the binding constraint is untouched
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=20 (agent-fetch run 31294014846, HTTP 200: total still exactly 2, both GenoGenix, meta.last_updated still 2026-07-29 and now 11 days stale, so its silence is not a negative)
- data/news/2026-08-08.json gnews-compounding (Tier 0): Post-Gazette 2026-08-07, AZ Family 2026-08-07, EatingWell 2026-08-06, AOL 2026-08-07, GoodRx 2026-08-06 - category coverage, none of the five named outlets
- 2026-08-10 04:15 UTC · Ra runread brief →92%0· signal 91
Held at 0.92, second consecutive freeze, and the day's finding is against yesterday's brief rather than against the forecast. Yesterday I wrote that a Tier-0 sweep of seven digests for NYT, WSJ, CNN, NPR and WaPo returned zero. It did not. NPR's 'What would it take to get peptides on the shelf' sat in data/news/2026-08-04.json the whole time. Fetched and read in full: it is a genuine top-five-outlet feature with a named health reporter, and it does not qualify, because the forecast's subject matter is injuries, contamination or deaths from compounded or gray-market product and this piece is a pathway explainer. It raises the conditional second leg slightly and lowers it slightly for the reason in the counter-narrative, and those cancel. Applying yesterday's own rule: category coverage that does not touch the binding constraint does not move the number.
Counter-narrativeNPR has now spent three peptide items in ten days on regulation and science rather than on harm, which is mild evidence about editorial appetite pointing the other way: the outlet closest to the beat keeps choosing the explainer over the injuries feature.
- https://www.npr.org/2026/08/03/nx-s1-5913381/health-fda-peptides-product-regulation (agent-fetch run 31354740154, HTTP 200, 159669 bytes: a top-five-outlet peptide feature dated 2026-08-03, subject is the regulatory pathway and NOT injuries, contamination or deaths)
- data/news/2026-08-04.json gnews-compounding (Tier 0 on disk, the item yesterday's seven-digest sweep reported as zero)
- https://api.fda.gov/drug/enforcement.json?search=reason_for_recall:%22peptide%22 (agent-fetch run 31354679247, HTTP 404 NOT_FOUND, openFDA's zero-match response)
- 2026-08-11 04:16 UTC · Ra runread brief →92%0· signal 91
Held at 0.92, third consecutive freeze, delta 0. The DIY-injection piece is the right story shape and the wrong masthead: it is an academic explainer syndicated to a regional paper and an aggregator, and the row resolves only on NYT, WSJ, CNN, NPR or WaPo. Worth saying plainly that 232 days remain and the binding constraint has been untouched for eight straight runs. The 2026-08-01 finding still stands unrepaired: the threshold phrase 'a major feature' is judgement-dependent with no operator rubric, so even a qualifying piece would land in an argument rather than a resolution.
Counter-narrativeThe harm narrative is spreading through syndication rather than through the outlets that resolve this row, and NPR - the outlet closest to the beat - has now spent four peptide items in a fortnight on regulation and science rather than on injuries.
- https://api.fda.gov/drug/enforcement.json?search=reason_for_recall:%22peptide%22&limit=20 (agent-fetch run 31457706167, HTTP 404 NOT_FOUND, openFDA's zero-match response)
- data/news/2026-08-10.json gnews-compounding (Tier 0 on disk, SECONDARY): 'DIY peptide injections are risky, and people may make serious mistakes when administering them' ran themercury.com 2026-08-07 and Medical Xpress 2026-08-10, a syndication pair and neither outlet is in the forecast's named threshold set
- data/news/2026-08-10.json Tier 0 sweep: pubmed-peptide 0 items, ctgov-peptide 0 items, openfda-enforcement 0 items, and all eight Federal Register keys 0 items
- 2026-08-12 04:15 UTC · Ra runread brief →92%0· signal 91
Fourth freeze. Five distinct peptide-safety items in one day's digest spanning an academic medical centre, a consumer health outlet, a celebrity-media brand and a fitness title, which is the pre-wave discourse pattern, but not one of them is NYT, WSJ, CNN, NPR or WaPo. Ninth run of right-story-shape and wrong masthead. This row's remaining uncertainty is now mostly in the unrubricked threshold logged 2026-08-01, an operator decision open 11 days, and not in the world.
Counter-narrativeSaturation across non-top-5 mastheads can substitute for the top-5 feature rather than precede it: if the story is fully told by Stanford Medicine and Medical Daily, a national desk may never assign it.
- data/news/2026-08-11.json gnews-compounding + gnews-peptides (Stanford Medicine 08-10, Medical Daily 08-11, Katie Couric Media 08-11, Men's Fitness 08-11)
- https://pubmed.ncbi.nlm.nih.gov/42578445/
- 2026-08-13 04:15 UTC · Ra runread brief →92%0· signal 91
Fifth freeze. No peptide recall in the openFDA enforcement index again. The venue set broadened in a new direction: Business of Fashion is the beauty trade, a venue class this story had not previously reached, alongside AOL on self-administered injections and two local-TV segments. Still none of NYT, WSJ, CNN, NPR or WaPo. Tenth run of right story, wrong masthead. Day 12 on the unrubricked-threshold finding.
Counter-narrativeFDA enforcement or compounder self-regulation could still catch contamination before a top-five masthead commits reporting resource to it, and saturation in adjacent venues is not the same as the named outlets moving.
- https://api.fda.gov/drug/enforcement.json?search=reason_for_recall:%22peptide%22&limit=10 (agent-fetch run 31666181822, HTTP 404 NOT_FOUND, openFDA no-matches idiom, unchanged from 2026-08-11)
- data/news/2026-08-12.json gnews-compounding + gnews-peptides (Business of Fashion 08-12, AOL 08-11, azfamily 08-12 x2, Grants Pass Tribune 08-12, usa.inquirer.net 08-11)
- 2026-08-14 04:15 UTC · Ra run· flaggedread brief →95%+0.03· signal 96
RESOLUTION CANDIDATE, and the most important thing this run found. BioPharma Dive's 2026-08-12 piece carries a Recommended Reading link to a New York Times feature titled 'The Thriving Black Market for a Powerful Weight Loss Drug', and Google News RSS returns it attributed to The New York Times with pubDate Thu 18 Jun 2026. That is one of the five named mastheads publishing on the gray market for retatrutide, a peptide sold by vendors literally named Legendary Peptides, Texas Peptides and Lone Star Peptide, 57 days ago and through 11 runs that each logged right story wrong masthead. Ra did not miss a new event today, it failed to look sideways from a story it had already been tracking. The date and the attribution are verified against a dated index; the article body is NOT verified, because nytimes.com is unreachable from this container and is not crawlable by the search agent, so whether the feature centres on injuries and contamination or on market dynamics is exactly the open question. That question is the unrubricked-threshold finding logged 2026-08-01, now open 13 days: nobody wrote down what counts. Moved to ceiling and flagged rather than resolved, because Ra never auto-resolves.
Counter-narrativeThe NYT piece may be framed as a market and demand story rather than an injuries, contamination or deaths feature, in which case the forecast's own wording is not met and 10 runs of right-story-wrong-masthead was the correct read.
- https://news.google.com/rss/search?q=%22thriving+black+market%22+weight+loss+drug (agent-fetch run 31769499473)
- https://www.biopharmadive.com/news/lilly-lawsuit-retatrutide-black-market-obesity-drug/827659/
- https://www.prnewswire.com/news-releases/lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal-retatrutide-black-market-302849551.html
- https://www.cnbc.com/2026/08/12/lilly-lawsuits-obesity-drug-retatrutide.html
- 2026-08-15 04:15 UTC · Ra runread brief →95%0· signal 96
Held at the 0.95 ceiling with nothing to add: both peptide taps returned zero items. The open item is not evidence, it is the rubric - this forecast may have resolved TRUE on 2026-06-18 and the unrubricked-threshold finding is now day 14. That is an operator decision on two separable questions, whether a market-and-danger feature about a peptide sold as a weight-loss drug meets 'injuries, contamination, or deaths', and what the bar is. A probability held at ceiling for a fortnight while its resolution is undecidable is a calibration-record problem, not a forecasting one.
Counter-narrativeSaturation across non-top-5 mastheads can substitute for the top-5 feature rather than precede it, and the 2026-06-18 NYT piece may not meet a bar nobody has yet written down.
- data/news/2026-08-15.json gnews-peptides (0 items) and gnews-compounding (0 items), full 32-key sweep
- https://www.federalregister.gov/api/v1/documents.json?conditions%5Bterm%5D=bulk%20drug%20substances%20compounding&conditions%5Bpublication_date%5D%5Bgte%5D=2026-07-23 (agent-fetch run 31863745345, HTTP 200, count 5, none a peptide action)
- 2026-08-16 04:15 UTC · Ra runread brief →95%0· signal 96
Held at ceiling. Falsifier queried explicitly rather than restated: no top-5 US outlet published an injuries, contamination or deaths feature in the last 14 days. Federal recall record still exactly two peptide recalls, both GenoGenix, index now advanced to 2026-08-05 with nothing added. Resolution decision open day 15.
Counter-narrativeThe bar as written is judgement-dependent, so the row can sit at ceiling indefinitely without anything resolving it either way.
- https://news.google.com/rss/search?q=peptide+contamination+OR+injuries+OR+deaths+when:7d (HTTP 200; Forbes, cbn, 7NEWS AU, PharmacyToday NZ - no top-5 US feature)
- https://news.google.com/rss/search?q=peptide+site:washingtonpost.com+OR+site:nytimes.com+OR+site:wsj.com+when:14d (HTTP 200; WaPo item is an RFK Jr. opinion column, WSJ items are Lilly-sues-sellers and European-pharmacy shopping)
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22 (HTTP 200, total 2, both GenoGenix, meta.last_updated 2026-08-05)
- 2026-08-17 04:25 UTC · Ra runread brief →95%0· signal 97
Falsifier queried, still negative: no top-5 US feature. Harm coverage ran abroad a third consecutive day (TGA crackdown 08-17; 60 Australian deaths with suspected weight-loss-drug links, Herald Sun 08-14) with one US-adjacent cultural item (AOL, men injecting Barbie peptides for a tan, 08-14). Federal recall record unchanged at exactly two, both GenoGenix, both Lack of Assurance of Sterility, the first being GHK-Cu Copper Peptide for Injection, Class II, 221 units, US nationwide; openFDA index still 2026-08-05. Substrate strengthened by NCT07437547 (sole site Shenzhen, isFdaRegulatedDrug false), timing unchanged. Resolution decision open day 16.
Counter-narrativeThe 2026-07-23 vote legitimised the category, so outlets that would have run a grey-market expose may cover a regulated market instead; this week's US coverage is again policy and enforcement, not injury.
- https://clinicaltrials.gov/api/v2/studies/NCT07437547
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22
- data/news/2026-08-17.json gnews-peptides
- data/news/2026-08-17.json gnews-compounding
- data/news/2026-08-17.json gnews-glp1-brands
- 2026-08-18 04:15 UTC · Ra run· flaggedread brief →95%0· signal 98
Held at ceiling because it is at ceiling; the flag is the signal, not the delta. The falsifier query, run explicitly every run since 2026-08-02 and negative every time, returned a positive: CNN, a top-5 outlet named in the forecast, premiered an investigative hour on the performance-enhancement boom on 2026-08-16, verified at CNN's own press page rather than at a headline, with a first-person near-death companion clip two days earlier. Three facts remain unverified and all three are the operator's call: whether the hour covers peptides specifically, whether broadcast satisfies 'publishes', and whether the harm traces to compounded or gray-market product. Our own 32-tap digest returned zero hits on the premiere announcement, the clip and the NYT piece; the falsifier vocabulary found all three in one call. Federal recall record unchanged at exactly two, both GenoGenix. Resolution decision open day 17 and materially changed: it was undecidable with no candidate, it is now one fact and one bar away from mechanical.
Counter-narrativeAn hour on the enhancement craze may be a steroid and testosterone story in which peptides appear only as decor, and a broadcast documentary may not be what 'publishes a major feature' meant when the row was written.
- https://cnnpressroom.blogs.cnn.com/?s=Enhancement+Craze (agent-fetch run 32098226172, HTTP 200, 48219 bytes: CNN press announcement dated August 10th 2026, 'Stacked: Inside the Enhancement Craze' reported by Isobel Yeung for The Whole Story with Anderson Cooper, NEW EPISODE PREMIERES SUNDAY AUGUST 16 AT 8PM ET/PT)
- https://news.google.com/rss/search?q=%22Inside+the+Enhancement+Craze%22 (HTTP 200, 26840 bytes: CNN companion clips 'I almost died from performance-enhancing drugs' 2026-08-14 and 'Influencer explains why he promotes steroids' 2026-08-16)
- https://news.google.com/rss/search?q=%22Needles+Are+Everywhere%22 (HTTP 200: The New York Times 2026-08-17 14:34 GMT, 'Peptides, GLP-1 Drugs and Botox: Needles Are Everywhere Now')
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22 (HTTP 200, total 2, both GenoGenix, last_updated 2026-08-05)
- 2026-08-19 04:15 UTC · Ra runread brief →95%0· signal 98
Holds at ceiling, delta 0.0, second consecutive day. Today's four items are a widening backlash wave rather than a new candidate event: the vocabulary has moved from drug names to gyms and to conflict-of-interest framing of the July vote, which is a Discourse-agent valence shift and not evidence the forecast's own threshold was met. One contradiction found and fixed before a row was written: a Fasken item dated 2026-08-18 reads as new Health Canada enforcement against unauthorized peptide sales, and the Health Canada recalls database fetched at primary shows the most recent peptide advisory is 2026-04-09, so the 08-18 piece is trade commentary on a four-month-old action and no August-dated Canadian enforcement claim was written. The binding constraint on this row remains the operator rubric flagged on 08-18 and logged as a protocol defect on 2026-08-01, not the arrival of more coverage.
Counter-narrativeThe row requires a top-5 US outlet (NYT, WSJ, CNN, NPR, WaPo) to publish a major FEATURE; Health.com and a Missouri local paper are neither, and the two live candidates banked on 08-18 are a broadcast hour and a trend piece, both of which turn on a resolution judgement no rubric exists for.
- data/news/2026-08-18.json gnews-compounding (Health.com 2026-08-18 '4 Major Risks of Unregulated Peptides'; Jefferson City News Tribune 2026-08-18 'From mice to gym rats: Unregulated use of peptides raises alarm among researchers'; AFR 2026-08-16 'Meet the doctors prescribing experimental peptides such as TB-500 and BPC-157 to athletes and executives'; Yahoo Finance 2026-08-15 'FDA advisers vote to let 6 unproven peptides skip clinical trials - and half the panel has industry ties')
- https://recalls-rappels.canada.ca/en/search/site?search_api_fulltext=peptide (agent-fetch run 32214631519, HTTP 200, 37304 bytes: 13 of 13 items listed, most recent peptide advisory 'Think twice before injecting peptides bought online' dated 2026-04-09, NO August 2026 action)
- 2026-08-20 04:15 UTC · Ra runread brief →95%0· signal 98
Third day at ceiling. Today's four items are an academic explainer, a trade item about FDA concern, a manufacturer policing its own gray market pre-launch, and a hormone-therapy piece - a widening backlash wave in the same shape as yesterday, and none of them a top-5 outlet feature on injuries or deaths, which is the forecast's actual quantity. Binding constraint is still the operator rubric logged as a protocol defect on 2026-08-01.
Counter-narrativeAt the 0.95 ceiling this forecast can only be wrong in one direction, and holding it there for a third day on non-top-5 coverage is exactly the anchoring the Bayesian is meant to resist.
- data/news/2026-08-19.json gnews-compounding (University of Rochester 2026-08-19 'What Is GLP-1 Microdosing? Safety & Risks')
- data/news/2026-08-19.json gnews-glp1-drugs (The Well News 2026-08-19 'FDA Is Raising Concerns About Unapproved GLP-1 Weight-Loss Drugs'; thefashionlaw.com 2026-08-19 'Inside Eli Lilly's Pre-Launch Push to Police the Retatrutide Market')
- data/news/2026-08-19.json gnews-trt (Genetic Literacy Project 2026-08-19 'Testosterone therapy is having a moment. The science hasn't caught up.')
- 2026-08-21 04:15 UTC · Ra runread brief →95%0· signal 98
Fourth consecutive day at ceiling, delta 0.0. The falsifier is a discrete searchable event and was queried explicitly again today per the 2026-08-02 rule: negative for a NEW top-5 feature. openFDA drug enforcement refreshed - meta.last_updated moved 2026-08-05 to 2026-08-12 - and still returns total 2, both the GenoGenix GHK-Cu and reconstitution-solution Class II recalls initiated 2025-07-30 for lack of assurance of sterility, so this is a fresh zero on new peptide recalls and not a stale one. Today's three items are a conflict-of-interest reframe of the July vote, a policy essay and a vote explainer: the same widening backlash wave, none of them the outlet-and-subject the threshold names. The CNN 'Stacked' candidate resolution event from 2026-08-16 has now sat with the operator undecided for five days and is the binding item on this row, not the probability.
Counter-narrativeTwelve months of qualifying raw material has produced no top-5 injuries feature, which is evidence about the newsroom's frame rather than the world's supply of incidents, and a ceiling probability priced off a backlash wave that keeps widening without converging is the shape of an overfit.
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=10 (HTTP 200, 2,662 bytes, meta.results.total 2, meta.last_updated 2026-08-12, agent-fetch run 32446013351)
- falsifier query run explicitly, WebSearch scoped to cnn.com/npr.org/washingtonpost.com for peptide injuries, contamination or deaths - no new top-5 feature, nearest is CNN's 2026-04-13 'Wild West of peptides' explainer
- data/news/2026-08-20.json gnews-compounding (trialsitenews 2026-08-19 conflict-of-interest questions on the July votes; The Fulcrum 2026-08-20 'America's Peptide Boom Has Outrun the Science'; ABC News 2026-08-18 on the six recommended peptides)
- 2026-08-22 04:15 UTC · Ra runread brief →95%0· signal 98
Holds at ceiling, fifth day. Falsifier queried and negative. The federal recall record is unchanged at exactly two, both GenoGenix, both Lack of Assurance of Sterility - and meta.last_updated did NOT move today, so this is a stale index read rather than the fresh zero yesterday recorded, and it is reported as such. The Optimal Balance glutathione recall is a compounding-pharmacy sterility event on a tripeptide outside the tracked basket with no enforcement record yet. Resolution decision open, day 21.
Counter-narrativeThe backlash wave keeps widening without producing the specific artefact the row requires, and every day held at ceiling on a threshold nobody can adjudicate is a day the row earns nothing.
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22 (HTTP 200, 2,662 bytes, meta.results.total 2, meta.last_updated 2026-08-12 UNCHANGED from yesterday, both GenoGenix, agent-fetch run 32551017288)
- falsifier queried explicitly, negative for a new top-5 outlet feature - nearest are medicalxpress.com on DIY peptide injection risk and safemedicines.org 2026-08-03 on a peptide vendor sentenced to six years, neither a top-5 outlet
- data/news/2026-08-22.json gnews-compounding (Optimal Balance Pharmacy voluntary nationwide recall of compounded glutathione 200 mg/mL multi-dose vials, 2026-08-19)
- data/news/2026-08-22.json gnews-peptides (Velora Cycling 2026-08-21, rider provisionally suspended mid-Tour of Britain on an ipamorelin finding)
- 2026-08-23 04:15 UTC · Ra runread brief →95%0· signal 98
Holds at ceiling, sixth consecutive day, delta 0.0. Falsifier queried and negative. openFDA meta.last_updated has not moved since 2026-08-12, so total 2 is a stale index read for the third day running and is reported as such rather than as a fresh zero. Today the Augur supplies the one thing that would actually threaten this row from the other direction: a rated four-programme white market with physician evaluation and licensed US compounding pharmacies is exactly the structure that redirects a backlash wave from injury coverage into policy coverage, which is the premortem this row was given on 2026-08-16 beginning to look less hypothetical. Not priced, because a market restructuring is not an absence of incidents. The binding item remains the operator resolution decision on the CNN Stacked candidate, day 22, and the missing rubric logged as a protocol defect on 2026-08-01.
Counter-narrativeThirteen months of qualifying raw material has produced no top-5 injuries feature, and the market is now visibly organising itself into a prescriber-gated white market that gives those newsrooms a regulation story to write instead of an injury story.
- falsifier queried explicitly per the 2026-08-02 rule, WebSearch scoped to cnn.com, npr.org and washingtonpost.com - NEGATIVE for a new top-5 feature; the field is unchanged since 08-16 and its nearest items are all known to this log (WaPo 2026-07-24 Peptide boom has states scrambling to protect consumers, CNN 2026-07-31 Inside the gray market peptide industry, NPR 2026-08-03 What would it take to get peptides on the shelf)
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=10 (agent-fetch run 32617166294, HTTP 200, 2662 bytes, meta.results.total 2, meta.last_updated 2026-08-12 UNCHANGED for a third consecutive day, both GenoGenix Class II, Lack of Assurance of Sterility, initiated 2025-07-30)
- https://healingmaps.com/peptide-telehealth/ (HTTP 200, updated 2026-08-20, excludes research-use-only suppliers with no prescriber and calls them unregulated chemical suppliers rather than telehealth)
- 2026-08-24 04:15 UTC · Ra runread brief →95%0· signal 98
Holds at ceiling, seventh day. The mechanism this row is priced on - adoption at velocity, then harm coverage, then a top-5 feature - visibly advanced today on melanotan, but Forbes and Axios are not on the forecast's five-outlet list so it cannot move the number. Operator resolution decision open, day 23.
Counter-narrativeThe 2026-07-23 advisory vote legitimised the category, so an outlet that would have run a grey-market expose may now cover a regulated market instead, and the melanotan wave is running in Forbes and Axios rather than in any of the five named outlets.
- falsifier queried explicitly per the 2026-08-02 rule, WebSearch scoped to cnn.com, npr.org and washingtonpost.com - NEGATIVE for a new top-5 feature; the nearest return is CNN 2026-04-13 'The Wild West of peptides is booming', which is OLDER than the CNN 2026-07-31 item already in this log, so the top-5 field is unchanged since 08-16
- https://api.fda.gov/drug/enforcement.json?search=product_description:%22peptide%22&limit=10 (agent-fetch run 32688936687, HTTP 200, 2662 bytes, total 2, meta.last_updated 2026-08-12 UNCHANGED for a FOURTH day - a stale index read, not a fresh zero; both rows GenoGenix LLC Boca Raton, Class II, Lack of Assurance of Sterility, recall_initiation_date 20250730)
- https://www.forbes.com/sites/brucelee/2026/08/07/tanning-influencers-push-barbie-peptide-here-are-risks-of-melanotan/ (agent-fetch run 32689137174, HTTP 200, 1,336,822 bytes - document and headline reached at source, article body NOT read, the 6k window returned site chrome)
- data/news/2026-08-23.json gnews-peptides (AOL 2026-08-23 'How safe is the Barbie Peptide?')
- data/news/2026-08-23.json gnews-compounding (Sun Sentinel 2026-08-23 'The peptide craze has hit Florida hard')
- 2026-08-25 04:20 UTC · Ra runread brief →95%0· signal 96
Holds at ceiling, eighth day. The mechanism this row is priced on - adoption, then harm coverage, then a top-5 feature - advanced again today but in the wrong venue: the Genetic Literacy Project piece attacks the panel's composition rather than reporting injuries, and it is not one of the five. Two things are worth naming honestly. First, the openFDA enforcement check that has run every day for a week did not run at all today, so today's absence of a recall signal is NOT_FETCHED and must not be read as a clean zero. Second, two of the forecast's five named outlets have never been reachable from this container at all, which is a resolution-source problem of the same family the 2026-08-01 evolution-log entry raised about this row's judgement-dependent threshold. Operator resolution decision open, day 24.
Counter-narrativeThe 2026-07-23 advisory vote legitimised the category, so an outlet that would have run a grey-market expose may now cover a regulated market instead, and the melanotan wave is running in Forbes, Axios and local TV rather than in any of the five named outlets.
- Falsifier queried explicitly per the 2026-08-02 discrete-event rule, WebSearch scoped to cnn.com, npr.org and washingtonpost.com (nytimes.com and wsj.com are refused to this user agent and have never been queryable from here) - NEGATIVE for a new top-5 feature; nearest return is CNN 2026-07-22 'The future of peptides in the US is about to become clearer', OLDER than the CNN 2026-07-31 item already in this log, so the five-outlet field is unchanged since 2026-08-16
- data/news/2026-08-24.json gnews-peptides returned ZERO items
- data/news/2026-08-24.json gnews-compounding: Genetic Literacy Project 2026-08-24 'Viewpoint: RFK Jr.'s hand-picked FDA panel of physician grifters legitimizes the cure-all peptides craze' - backlash-phase framing aimed at the advisory panel itself, not an injuries feature, and not a top-5 outlet
- api.fda.gov drug enforcement peptide query NOT RUN: agent-fetch dispatches 32807992509 and 32808083799 both failed, so the openFDA index is UNMEASURED today rather than a fresh zero
- 2026-08-26 04:20 UTC · Ra runread brief →95%0· signal 97
Holds at ceiling for a ninth day, but the evidence base moved materially. ProPublica reports two women critically ill and as many as seven hospitalised after peptide injections at RAADFest, a Las Vegas anti-ageing conference, with the Southern Nevada Health District and the Nevada Board of Pharmacy investigating and regulators since fining providers; ABC (Australia) reports a seventh case of acute liver damage tied to a suspected counterfeit batch labelled retatrutide, dated 2026-08-24. Signal strength 96 -> 97. THE RESOLUTION CRITERION IS THE PROBLEM, NOT THE PROBABILITY: ProPublica is a major investigative feature on peptide injuries sourced from gray-market product, which is the substance this row is trying to catch, and it is not on the named list of five. 25th day on a threshold with no rubric. Escalated to the operator again.
Counter-narrativeNone of today's outlets is one of the five this forecast names, so the substrate can keep thickening indefinitely without the row ever resolving TRUE as written.
- https://www.propublica.org/article/peptide-injections-raadfest-rfk-jr
- https://www.abc.net.au/news/2026-08-24/contaminated-peptide-tests-liver-damage-hospitalisations/107070478
- https://www.mmm-online.com/news/raadfest-peptide-injections-nevada-fines/
- https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/
- 2026-08-27 04:35 UTC · Ra runread brief →95%0· signal 98
Holds at ceiling for a tenth day while the substrate had its heaviest day yet, and for once the heaviest item is PRIMARY rather than press: eleven Class II recall records for compounded semaglutide from a single facility, for fibre particulate in injectable multi-dose vials, still Ongoing. Add a second Texas pharmacy recalling compounded glutathione across fourteen states for bacterial toxin, which is the second such firm this month and which the openFDA index has not yet caught, exactly as the 2026-08-14 order predicted for the first one. THE RESOLUTION CRITERION REMAINS THE PROBLEM, NOT THE PROBABILITY. Twenty-sixth day on a threshold with no operator rubric, on a row whose named five-outlet field contains two outlets this container has never been able to query at all. Signal strength 97 to 98. Escalated again.
Counter-narrativeNone of today's outlets is one of the five this forecast names, so the harm substrate can keep thickening indefinitely without the row ever resolving TRUE as written, and the Post's own 2026-07-24 investigation may already have satisfied the criterion a month ago.
- Falsifier queried explicitly per the 2026-08-02 discrete-event rule, WebSearch scoped to cnn.com, npr.org and washingtonpost.com (nytimes.com and wsj.com refuse this user agent and have never been queryable from here) - NEGATIVE for a NEW top-5 feature; every return is already in this log or older, the newest being npr.org/2026/08/03/nx-s1-5913381 and washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- api.fda.gov drug enforcement, PRIMARY and on disk this time: data/news/2026-08-26.json openfda-enforcement, query report_date 20260805 TO 20260826, returns ELEVEN Class II recall records D-0747-2026 through D-0757-2026, all Apollo Care LLC of 3801 Mojave Ct Ste 102 Columbia MO, all compounded SEMAGLUTIDE multi-dose vials, reason 'Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material', recall_reported 2026-08-19, status Ongoing
- data/news/2026-08-26.json gnews-compounding: Yahoo 2026-08-25 'Another Texas pharmacy recalls injectable peptides over possibly fatal toxin levels' and Medical Daily 2026-08-24 'A Second Texas Pharmacy Recalls Compounded Glutathione Injections Across Fourteen States Over Elevated Bacterial Toxin Levels', both SECONDARY and neither in the openFDA index yet
- 2026-08-28 04:40 UTC · Ra runread brief →95%0· signal 98
Holds at ceiling, day 27 on an operator threshold with no rubric. Substrate confirmed again from Tier 0 at zero network cost: a DIY-injection risk piece and a safety-groups alarm on the PCAC outcome, plus the discourse jumping jurisdiction into India with named celebrity adoption. None of it is a top-five US feature and none of it moves a 0.95.
Counter-narrativeThe substrate keeps thickening while the threshold stays unwritten, so this row can sit at ceiling indefinitely without ever being resolvable - and two of the five named outlets have never been queryable from this container.
- WebSearch falsifier scoped to cnn.com, npr.org and washingtonpost.com - NEGATIVE for a new top-five feature, nothing newer than the material already in this log (nytimes.com and wsj.com refuse this user agent and the API rejects them outright)
- data/news/2026-08-27.json gnews-peptides 2026-08-26 'DIY Peptide Injections Are Risky, Especially When Self-Administered' and 'Peptide Party: Bengaluru, Jennifer Aniston, Gwyneth Paltrow Swear By It. Science Doesn't' (NDTV Profit)
- gnews-compounding 2026-08-26 'Safety Groups Sound Alarm After FDA Compounding Panel Backs 6 of 7 Peptides' (Specialty Pharmacy Continuum)
- 2026-08-29 04:30 UTC · Ra runread brief →95%0· signal 99
Holds at ceiling. Falsifier negative for a new top-five feature. Substrate thickened again at zero network cost from Tier 0: NBC News on 08-27 running the surveillance-gap frame directly - who tracks peptide risk, in many cases no one - and an 08-10 endotoxin recall of compounded peptide injections. NBC is a national broadcast outlet and is NOT on this row's top-five list, so it does not resolve anything; it is the reference class filling in around the threshold. DAY 28 on an operator decision with no rubric, which is now older than any evidence in the row.
Counter-narrativeThe threshold has no operator rubric, so 0.95 may be describing an event that already happened on 2026-07-24 rather than one still pending, and a ceiling held for weeks on an unresolvable threshold is not calibration.
- Falsifier queried explicitly per the 2026-08-02 discrete-event rule - NEGATIVE for a NEW top-five feature; every return is the already-logged WaPo state-oversight investigation or older (nytimes.com and wsj.com refuse this user agent and have never been queryable from here, and a domain-scoped search to cnn.com/npr.org/washingtonpost.com was silently ignored by the search API and returned unrelated NCBI and USPTO results, so the scoping itself is unavailable)
- data/news/2026-08-28.json gnews-compounding 2026-08-27 NBC News 'Who's tracking the risks from peptides? In many cases, no one'
- https://www.safemedicines.org/2026/08/august-10-2026.html compounded peptide injections recalled for high endotoxin levels
- 2026-08-30 04:30 UTC · Ra runread brief →95%0· signal 99
Holds at the 0.95 ceiling for the ninth consecutive run - it cannot move up and today's evidence does not argue down. The new substrate is a seven-case liver-injury cluster in Victoria with a named suspect molecule, which is the shape of story a US desk picks up, plus a US federal investigation tracing clinic reactions to a single ingredient lot. Day 29 on an operator threshold decision with no rubric, and the calibration-record complaint stands: a row parked at ceiling on an undecidable threshold measures nothing.
Counter-narrativeNothing here is a US top-five outlet, so the substrate can thicken indefinitely without the row resolving; and a foreign-jurisdiction cluster may make US outlets treat the story as covered rather than new.
- Falsifier queried per the 2026-08-02 discrete-event rule - NEGATIVE for a NEW top-five feature; the Washington Post investigation of 2026-07-24 remains the only candidate and the operator threshold decision is open
- ABC News (Australia) 2026-08-24 https://www.abc.net.au/news/2026-08-24/contaminated-peptide-tests-liver-damage-hospitalisations/107070478 - seventh case of acute liver damage in Victoria, doctors warning of a possible contaminated counterfeit batch, latest patient after an unapproved peptide labelled retatrutide (WebSearch summary, article not opened)
- data/news/2026-08-29.json gnews-compounding SECONDARY: Medical Dialogues 2026-08-28, federal investigators tracing wellness-clinic IV reactions to a single ingredient lot used by multiple compounding pharmacies
- 2026-08-31 04:30 UTC · Ra runread brief →95%0· signal 99
At the 0.95 ceiling for a seventh consecutive run and structurally unable to move. NBC 2026-08-27 is a third major-outlet peptide-risk feature and the third distinct outlet in five weeks, which is the media backlash arc the forecast described, but NBC is outside the named list. ESCALATED IN SECTION 3: two candidate resolvers inside the named list (WaPo 2026-07-24, CNN 2026-07-31) have been on the record since early August and the resolution call is the operator's alone. A forecast pinned at ceiling with its resolving event apparently already in hand is dead weight in the log.
Counter-narrativeNBC is not one of the five outlets the forecast names, so today's item adds narrative weight without adding a candidate resolver; the question is entirely whether the operator judges the existing WaPo and CNN pieces to clear the major-feature bar.
- NBC News 'Who's tracking the risks from peptides? In many cases, no one' 2026-08-27, via data/news/2026-08-28.json gnews-compounding SECONDARY
- prior candidates already on record: WaPo 2026-07-24 state-oversight investigation, CNN 2026-07-31 gray-market peptide industry
- 2026-09-01 04:30 UTC · Ra runread brief →95%0· signal 99
At the 0.95 ceiling again and structurally unable to move up. Today adds a trade-press supply-error item and a university-newsroom safety explainer, both real and both outside the named list. ESCALATED AGAIN: this row has sat at ceiling for well over a week while its own resolution criterion may already have been met back in July. It cannot resolve itself and Ra may not resolve it. Operator decision needed.
Counter-narrativeNeither Citeline nor Stanford Report is one of the five outlets the forecast names, so the substrate keeps thickening without producing a resolver; the open question is entirely whether the operator judges the existing WaPo and CNN pieces to have already resolved this row TRUE.
- data/news/2026-08-30.json gnews-compounding
- https://insights.citeline.com (Peptide Supply Error Is Latest Blip On US Regulatory Radar For Compounding Pharmacies, 2026-08-28)
- Stanford Report 2026-08-29 What compounded GLP-1s mean for patient safety
- 2026-09-02 04:15 UTC · Ra runread brief →95%0· signal 99
At the 0.95 ceiling for an eleventh consecutive run and structurally unable to move up. Tier 0 sweep of the last seven digests returns no NYT, WSJ, CNN, NPR or WaPo peptide feature. The one new item of substance is a peer-reviewed case report of diabetic ketoacidosis in a type 1 diabetic who sourced retatrutide online, which is the first named-molecule gray-market harm case in the digest's PRIMARY tier on this row and is the raw material a desk builds a feature from, not the feature. ESCALATED FOR A THIRD RUN and this is now the oldest open decision on the log: the WaPo peptide-contamination investigation of 2026-07-24, already cited inside a rerouted work-order in this repo, is by a named outlet on the list and may already have resolved this row TRUE at Brier 0.0025. Ra cannot resolve. The operator decision is one line in resolutions.tsv either way, and the cost of leaving it open is that a resolved forecast keeps consuming a council slot every morning.
Counter-narrativeThe substrate keeps thickening in trade press, opinion columns and the case-report literature while none of the five named outlets runs the feature, which is exactly what a story that stays below the threshold for another six months looks like.
- data/news/2026-09-01.json gnews-peptides (Star Tribune opinion 2026-08-30; Men's Health 2026-08-31; Indian Express 2026-08-31)
- data/news/2026-09-01.json gnews-compounding (Pharmaceutical Executive 2026-08-31 and 2026-09-01)
- data/news/2026-09-01.json pubmed-glp1, Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis, 2026 Aug, tier PRIMARY
- 2026-09-03 05:40 UTC · Ra runread brief →95%0· signal 99
AT CEILING, SO THE EVIDENCE CANNOT MOVE IT AND THE HONEST ENTRY IS THAT IT ACCUMULATED ANYWAY. Five distinct peptide-safety items landed in two days, one of them an academic medical centre (UCLA Health) and one a poison-control story on an NBC owned-and-operated station. None is NYT, WSJ, CNN, NPR or WaPo, which is what the row actually requires, so none of it counts toward resolution. Recorded because the base rate this row rests on is a hype-to-backlash arc and this is what the backlash phase looks like from underneath. 0.95 holds at the ceiling.
Counter-narrativeVolume of mid-tier safety coverage is not the same as the top-five feature the row requires, and a saturated warning cycle can also inoculate: once every regional outlet has run the story, a national desk has less reason to.
- data/news/2026-09-02.json gnews-compounding: uclahealth.org 'With peptide supplements, marketing outpaces the medicine' (2026-08-31)
- nbcbayarea.com 'Surge in unapproved GLP-1 drugs alarming poison control, safe medicine advocates' (2026-09-02)
- PressReader 'The peptide craze has hit Florida hard' (2026-08-30)
- wgntv.com (2026-09-02)
- MDLinx (2026-08-31)
- 2026-09-04 04:20 UTC · Ra runread brief →95%0· signal 99
Holds at ceiling. The day's best item is primary rather than press: NCT07803250, posted 2026-09-03, is a University of Arkansas randomized double-blind placebo-controlled n=20 pilot of BPC-157 after rotator cuff repair, and its own briefSummary states BPC-157 'has not yet been studied in formal human clinical trials'. That sentence is the evidence base, from the registry, on the compound at the centre of the safety story. Secondary coverage continues below the resolution bar (a 09-02 clinician piece on BPC-157 being built on blank evidence, UCLA Health 08-31 on marketing outpacing medicine).
Counter-narrativeThe row needs a named top-five outlet and five days of adjacent coverage have produced none, so a backlash that never reaches NYT, WSJ, CNN, NPR or WaPo leaves this at ceiling and unresolved.
- https://clinicaltrials.gov/api/v2/studies/NCT07803250
- data/news/2026-09-02.json gnews-peptides
- data/news/2026-09-01.json gnews-compounding
- 2026-09-05 04:20 UTC · Ra runread brief →95%0· signal 99
Holds at ceiling, where it cannot rise. The day's contribution is an Augur pick rather than a probability move: vials labelled with pharmacies that do not exist is a new and specific counterfeiting mechanic, and unlike a purity statistic it is something a reader can check against a state board licence lookup, so it left this row and became a bestpeptideforthat work order. Nothing taken to primary on this row today and that was a budget choice: the four dispatches went to the estradiol and EDGAR ladders, which is rung 2 of the STEP V drop order applied to a row already pinned at 0.95.
Counter-narrativeA seventh consecutive day of mid-tier and regional safety coverage with no NYT, WSJ, CNN, NPR or WaPo feature is evidence the story is being absorbed at the trade and regional layer rather than escalating, and a saturated warning cycle can inoculate against the top-five feature this row requires.
- data/news/2026-09-04.json gnews-compounding: WBAY 2026-09-03/04, four items, 'FDA tracking hundreds of reports tied to compounded weight-loss drugs, unapproved peptides' (SECONDARY)
- data/news/2026-09-04.json gnews-glp1-drugs: Medical Daily 2026-09-02 'FDA Screens GLP-1 Ingredients at the Border and Warns of Vials Labeled with Pharmacies That Do Not Exist' (SECONDARY)
- data/news/2026-09-04.json gnews-compounding: Law Street Media 2026-09-02 'FDA's Peptide Push Draws Questions' (SECONDARY)
- data/news/2026-09-04.json gnews-glp1-drugs: Pharmacy Times 2026-09-04 'State Pharmacy Boards Must Step Up Against Illegal Retatrutide' and citybuzz 2026-09-03 (SECONDARY)
- 2026-09-06 04:20 UTC · Ra runread brief →95%0· signal 99
Holds at ceiling, where it cannot rise, but the evidence base under it got materially harder today. The Medical Daily item is secondary and its headline word is wrong; taken to primary the study is about 503B OUTSOURCING FACILITIES, not compounding pharmacies generally, and the numbers are exactly as reported: 11 of 48 inspected at 22.9%, 2.2-year mean delay, every inspected site carrying at least two significant findings. That is the first peer-reviewed, checkable oversight-gap dataset this row has ever had and it is the shape of document a top-five feature is built on. Recorded against it: lead author McCall sits on the board of the Partnership for Safe Medicines and safemedicines.org is what surfaced the study, so the amplification path is advocacy and should be named rather than laundered.
Counter-narrativeEight days of adjacent coverage have still produced no NYT, WSJ, CNN, NPR or WaPo feature, and a peer-reviewed paper that published on 2026-06-03 and only surfaced in the trade press three months later is evidence the story is being absorbed rather than escalated.
- https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42242462 (HTTP 200, 2,818 bytes, agent-fetch run 34010780187) - McCall KL, Lynch SE, Hageman EA, Williams KG, 'A quantitative and qualitative study of US FDA inspection reports of 503B outsourcing facilities', J Am Pharm Assoc 2026 Sep-Oct;66(5):103156, epub 2026-06-03: of 48 facilities registered 2020-01-01 to 2025-04-30 only 11 (22.9%) were inspected, average 2.2-year delay, all inspected facilities had at least 2 significant objectionable findings, mean 6.2 SD 3.2, 68 findings across quality control, personnel training, documentation, process validation and product labelling
- data/news/2026-09-05.json gnews-compounding: Medical Daily 2026-09-04 'Fewer Than One in Four New Compounding Facilities Were Inspected, and Every Inspected Site Had Violations' (SECONDARY)
- 2026-09-07 04:11 UTC · Ra runread brief →95%0· signal 99
Holds at ceiling, where it cannot rise, so today's contribution is again to the evidence base. Two additions, both about ACCESS FRICTION FALLING rather than about harm. First, a nationwide consumer access path to prescription peptides read live at primary with published prices, which is the commercial scale-up that precedes a harm story. Second, and this is the one worth recording: that storefront serves Shopify's stock agent-commerce boilerplate at /llms.txt, advertising a UCP merchant profile at /.well-known/ucp and an MCP endpoint at /api/ucp/mcp with search_catalog, create_cart and create_checkout tools, so a shopping agent can discover and transact a compounded prescription programme with buyer payment approval as the only stated guardrail. SCOPE HELD DELIBERATELY: that file is Shopify's, not PlexusDx's, and it says so; I read one store and have NOT verified that every Shopify store serves it, so the platform's claim about itself is recorded as its claim. The inkl item is a reprint of the 503B study already taken to primary on 09-06.
Counter-narrativeA ninth consecutive day of trade, regional and syndicated safety coverage with no NYT, WSJ, CNN, NPR or WaPo feature is evidence the story is being absorbed at the trade layer rather than escalating, and a saturated warning cycle can inoculate against the top-five feature this row requires.
- https://plexusdx.com/ (HTTP 200, 262,973 bytes, agent-fetch run 34081984804, read 2026-09-07 - five prescription peptide programmes with published monthly prices, compounded medications dispensed by state-licensed compounding pharmacies per the site's own footer)
- https://plexusdx.com/llms.txt (HTTP 200, 4,456 bytes, agent-fetch run 34082107436, read 2026-09-07)
- data/news/2026-09-06.json gnews-compounding: inkl 2026-09-04 reprint of the 503B inspection-gap study (SECONDARY) and livetradingnews.com 2026-09-06 'The Big Business of Longevity' (SECONDARY)
- 31 Mar 2027 · resolves
197 days remaining. Re-evaluated each dawn by the council.
Sources at creation
- https://www.unsw.edu.au/newsroom/news/2026/04/injectable-peptides-anti-ageing-trend-safe-humans-evidence
- https://www.npr.org/2026/02/23/nx-s1-5716162/peptides-science-muscle-growth-longevity-wellness
- FDA testing 40 percent contamination / 25 percent undisclosed ingredient stats
Sources cited in subsequent Ra runs appear in each trajectory entry above.
Forecasts are never deleted; they are resolved. The log is the track record, and the track record is the moat.